The Effects of Standard and Low Molecular Weight Heparin on Bone Nodule Formation In Vitro

Summary

Previously, we demonstrated in a rat model of heparin-induced osteoporosis that low molecular weight heparin (LMWH) produces less bone loss than unfractionated heparin, and that only heparin increases osteoclast number and activity. In contrast, both heparin and LMWH were found to decrease osteoblast function to a similar extent, possibly because at the doses tested both agents produced maximal inhibition. To examine the relative effects of heparin and LMWH on osteoblast function more closely we used an in vitro bone nodule assay, together with measurements of alkaline phosphatase (ALP) activity. Both agents inhibited bone nodule formation and ALP activity in a concentration-dependent manner, but 6 to 8-fold higher concentrations of LMWH were required to achieve equivalent effects. The effect of heparin on osteoblast function was both chain-length and negative charge-dependent because the ability of defined heparin fragments to inhibit nodule formation correlated with their molecular weight (r = 0.98), and N-desulfated heparin was less inhibitory than heparin. In contrast, the effect of heparin on osteoblast function was pentasaccharide-independent because heparin with low affinity for antithrombin had similar activity to heparin with high antithrombin activity. These findings help to explain mounting clinical evidence that the risk of osteoporosis is lower with LMWH than with heparin.

• References

• 1 Barbour LA, Kick SD, Steiner JF, Loverde ME, Heddleson LN, Lear JL, Baron AE, Barton PL. A prospective study of heparin-induced osteoporosis in pregnancy using bone densitometry. Am J Obstet Gynecol 1994; 170: 862-9.
• 2 Dahlman TC, Sjoberg HE, Ringertz H. Bone mineral density during long-term prophylaxis with heparin in pregnancy. Am J Obstet Gynecol 1994; 170: 1315-20.
• 3 Douketis JD, Ginsberg JS, Burrows RF, Duku EK, Webber CE, Brill-Edwards P. The effects of long-term heparin therapy during pregnancy on bone density. Thromb Haemost 1996; 75: 254-7.
• 4 Dahlman TC. Osteoporotic fractures and the recurrence of thromboembolism during pregnancy and the puerperium in 184 women undergoing thromboprophylaxis with heparin. Am J Obstet Gynecol 1993; 168: 1265-70.
• 5 Haram K, Hervig T, Thordarson H, Aksnes L. Osteopenia caused by heparin treatment in pregnancy. Acta Obstet Gynecol Scand 1993; 72: 674-5.
• 6 Ginsberg JS, Kowalchuk G, Hirsh J, Brill-Edwards P, Burrows R, Coates G, Webber C. Heparin effect on bone density. Thromb Haemost 1990; 64: 286-9.
• 7 Murphy MS, John PR, Mayer AD, Buckels JAC, Kelly DA. Heparin therapy and bone fractures. Lancet 1992; 340: 1098.
• 8 Monreal M, Olive A, Lafoz E, Del Rio L. Heparins, coumarin, and bone density. Lancet 1991; 338: 706.
• 9 Monreal M, Lafoz E, Olive A, Del Rio L, Vedia C. Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contraindications to coumarin. Thromb Heamost 1994; 71: 7-11.
• 10 Melissari E, Parker CJ, Wilson NV, Monte G, Kanthou C, Pemberton KD, Nicolaides KH, Barrett JJ, Kakkar V. Use of low molecular weight heparin in pregnancy. Thromb Haemost 1992; 68: 652-6.
• 11 Muir JM, Weitz JI, Andrew M, Young E, Shaughnessy SG. A histomorphometric comparison of the effects of heparin and low molecular weight heparin on cancellous bone in rats. Blood 1997; 89: 3236-42.
• 12 Shaughnessy SG, Young E, Deschamps Hirsh J. The effects of low molecular weight and standard heparin on calcium loss from fetal rat calvaria. Blood 1995; 86: 1368-73.
• 13 Rungby J, Kassem M, Eriksen EF, Danscher G. The von Kossa reaction for calcium deposits: silver lactate staining increases sensitivity and reduces background. Histochemical journal 1993; 25: 446-51.
• 14 Bellows CG, Aubin JE, Heersche JNM, Antosz ME. Mineralized bone nodules formed in vitro from enzymatically released rat calvaria cell populations. Calcif Tissue Int 1986; 38: 143-54.
• 15 Shibata Y, Abiko Y, Goto K, Moriya Y, Takiguchi H. Heparin stimulates the collagen synthesis in mineralized cultures of the osteoblast-like cell line, MC3T3-E1. Biochem Int 1992; 28: 335-44.
• 16 Hurley MM, Kessler M, Gronowicz Raisz LG. The interaction of heparin and basic fibroblast growth factor on collagen synthesis in 21 day fetal rat calvariae. Endocrinology 1992; 130: 2675-82.
• 17 Malaval L, Modrowski D, Gupta AK, Aubin JE. Cellular expression of bone-related proteins during in vitro osteogenesis in rat bone marrow stromal cell cultures. J Cell Phys 1994; 158: 555-72.
• 18 Teitelbaum SL, Molecular defects of bone development, in Favus MJ. (ed): Primer on the metabolic bone diseases and disorders of mineral metabolism, 2nd edition. New York: Raven Press; 1993. p 11.
• 19 Young E, Prins M, Levine MN, Hirsh J. Heparin binding to plasma proteins, an important mechanism for heparin resistance. Thromb Haemost 1992; 67: 639-43.
• 20 Young E, Wells P, Holloway S, Weitz JI, Hirsh J. Ex-vivo and in vitro evidence that low-molecular-weight heparins exhibit less binding to plasma proteins than unfractionated heparin. Thromb Haemost 1994; 71: 300-4.
• 21 Cosmi B, Fredenburgh JC, Rischke RT, Hirsh J, Young E, Weitz JI. Effect of nonspecific binding to plasma proteins on antithrombin activities of unfractionated heparin, low-molecular-weight heparin and dermatan sulfate. Circ. 1997; 95: 118-24.
• 22 de Romeuf C, Mazurier C. Heparin binding assay of von Willebrand factor (vWF) in plasma milieu: evidence of the importance of multimerization degree of of vWF. Thromb Haemost 1993; 69: 436-40.
• 23 Barzu T, Molho P, Tobelem G, Petitou M, Caen JP. Heparin degradation in the endothelial cells. Thromb Res 1987; 47: 601-9.
• 24 Barzu T, Molho P, Tobelem G, Petitou M, Caen J. Binding and endocytosis of heparin by human endothelial cells in culture. Biochim Biophys Acta 1985; 845: 196-203.
• 25 Bleiberg I, MacGregor I, Aronson M. Heparin receptors on mouse macrophages. Thromb Res 1983; 29: 53-61.
• 26 Hurley MM, Kream BE, Raisz LG. Structural determinants of the capacity of heparin to inhibit collagen synthesis in 21-day fetal rat calvariae. J Bone Min Res. 1990; 5: 1127-32.
• 27 Sakamoto S, Sakamoto M, Goldberg L, Colarusso L, Gotoh Y. Mineralization induced by B-glycerophosphate in cultures leads to a marked increase in collagenase synthesis by mouse osteogenic MC3T3-E1 cells under subsequent stimulation with heparin. Biochem Biophys Res Com 1989; 162: 773-80.
• 28 Levine MN, Hirsh J, Gent M, Turpie AG, Cruickshank M, Weitz J, Anderson D, Johnson M. A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin. Arch Intern Med 1994; 154: 49-56.